News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,656 Results
Type
Article (14250)
Company Profile (105)
Press Release (259293)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88268)
Career Advice (466)
Deals (15392)
Drug Delivery (73)
Drug Development (36712)
Employer Resources (50)
FDA (6378)
Job Trends (6234)
News (150692)
Policy (14125)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (442)
Accelerated approval (13)
Adcomms (8)
Allergies (66)
Alliances (23317)
ALS (56)
Alzheimer's disease (475)
Antibody-drug conjugate (ADC) (98)
Approvals (6567)
Artificial intelligence (200)
Autoimmune disease (38)
Automation (10)
Bankruptcy (150)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (117)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (168)
Cancer (1306)
Cardiovascular disease (151)
Career advice (417)
Career pathing (13)
CAR-T (47)
CDC (6)
Cell therapy (147)
Cervical cancer (9)
Clinical research (32005)
Collaboration (713)
Compensation (318)
Complete response letters (32)
COVID-19 (777)
CRISPR (43)
C-suite (423)
Cystic fibrosis (58)
Data (1806)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1379)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (112)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33442)
Editorial (19)
Employer branding (4)
Employer resources (45)
Events (38951)
Executive appointments (527)
FDA (7467)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (424)
Gene editing (68)
Generative AI (18)
Gene therapy (162)
GLP-1 (438)
Government (1401)
Grass and pollen (4)
Guidances (163)
Healthcare (3574)
HIV (11)
Huntington's disease (8)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (49)
Infectious disease (839)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (23)
Intellectual property (111)
Interviews (60)
IPO (5913)
IRA (33)
Job creations (2056)
Job search strategy (374)
JPM (27)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3448)
Liver cancer (22)
Longevity (8)
Lung cancer (181)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (406)
MASH (66)
Medical device (1301)
Medtech (1307)
Mergers & acquisitions (9894)
Metabolic disorders (431)
Multiple sclerosis (44)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (36)
Neuroscience (878)
Neurotech (1)
NextGen: Class of 2026 (1589)
Non-profit (600)
Now hiring (18)
Obesity (225)
Opinion (141)
Ovarian cancer (39)
Pain (107)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (220)
Patient recruitment (115)
Peanut (12)
People (29728)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (8301)
Phase II (13513)
Phase III (12206)
Pipeline (1851)
Policy (132)
Postmarket research (1401)
Preclinical (3338)
Press Release (25)
Prostate cancer (84)
Psychedelics (15)
Radiopharmaceuticals (134)
Rare diseases (340)
Real estate (2659)
Recruiting (18)
Regulatory (10933)
Reports (15)
Research institute (573)
Resumes & cover letters (55)
Rett syndrome (4)
RNA editing (6)
RSV (19)
Schizophrenia (68)
Series A (80)
Series B (47)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (80)
Sponsored (9)
Startups (1644)
State (2)
Stomach cancer (5)
Supply chain (48)
Tariffs (67)
The Weekly (45)
Vaccines (231)
Venture capital (31)
Weight loss (139)
Women's health (26)
Worklife (4)
Date
Today (25)
Last 7 days (181)
Last 30 days (791)
Last 365 days (10495)
2026 (801)
2025 (10712)
2024 (12498)
2023 (14246)
2022 (19557)
2021 (20068)
2020 (19034)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12421)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (318)
Alabama (18)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20880)
Australia (2686)
California (3151)
Canada (1467)
China (545)
Colorado (141)
Connecticut (128)
Delaware (122)
Europe (40846)
Florida (596)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (343)
India (41)
Indiana (238)
Iowa (2)
Japan (243)
Kansas (77)
Kentucky (20)
Louisiana (3)
Maine (2)
Maryland (419)
Massachusetts (2573)
Michigan (45)
Minnesota (163)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1389)
New Mexico (7)
New York (898)
North Carolina (614)
North Dakota (2)
Northern California (1434)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (711)
Puerto Rico (11)
Rhode Island (17)
South America (506)
South Carolina (10)
Southern California (1373)
Tennessee (52)
Texas (451)
United States (12571)
Utah (58)
Virginia (158)
Washington D.C. (42)
Washington State (219)
West Virginia (1)
Wisconsin (36)
Wyoming (1)
273,656 Results for "acelrx pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
AcelRx Pharmaceuticals, Inc. today announced the rebranding of the Company, with a name change to Talphera, Inc. (“Talphera”).
January 9, 2024
·
6 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc. today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora).
March 14, 2023
·
9 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
AcelRx Pharmaceuticals, Inc. today announced the publication of a quantitative market research study evaluating current U.S. physician anticoagulation use during continuous renal replacement therapy (CRRT) in patients with acute kidney injury in the intensive care unit.
December 12, 2023
·
8 min read
Biotech Bay
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion on its lead candidate Niyad™ (nafamostat) for use as an anticoagulant in dialysis circuits.
November 7, 2023
·
7 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced the closing of its divestment of DSUVIA® to Alora Pharmaceuticals.
April 5, 2023
·
6 min read
Business
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2023 financial results after market close on Wednesday, November 8, 2023.
October 26, 2023
·
1 min read
Biotech Bay
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) today announced that it is advancing Niyad™ (a lyophilized formulation of nafamostat) into a registrational study following the recent approval of an Investigational Device Exemption (IDE) submission to the United States Food and Drug Administration (FDA).
October 3, 2023
·
6 min read
Business
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, reported its third quarter 2023 financial results and provided a corporate update.
November 8, 2023
·
11 min read
Business
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2023 financial results and provided a corporate update.
May 10, 2023
·
9 min read
Business
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2023 financial results and provided a corporate update.
August 10, 2023
·
12 min read
1 of 27,366
Next
